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2352-3042/Copyright ª 2014, ChongqAbstract Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into
various mesodermal lines forming fat, muscle, bone, and other lineages of connective tissue.
MSCs possess plasticity and under special metabolic conditions may transform into cells of un-
usual phenotypes originating from ecto- and endoderm. After transplantation, MSCs release
the humoral factors promoting regeneration of the damaged tissue. During last five years, the
numbers of registered clinical trials of MSCs have increased about 10 folds. This gives evidence
that MSCs present a new promising resource for cell therapy of the most dangerous diseases.
The efficacy of the MSCs therapy is limited by low possibilities to regulate their conversion into
cells of damaged tissues that is implemented by the pRb-E2F signaling. The widely accepted
viewpoint addresses pRb as ubiquitous regulator of cell cycle and tumor suppressor. However,
current publications suggest that basic function of the pRb-E2F signaling in development is to
regulate cell fate and differentiation. Through facultative and constitutive chromatin modifica-
tions, pRb-E2F signaling promotes transient and stable cells quiescence, cell fate choice to
differentiate, to senesce, or to die. Loss of pRb is associated with cancer cell fate. pRb regulates
cell fate by retaining quiescence of one cell population in favor of commitment of another or by
suppression of genes of different cell phenotype. pRb is the founder member of the “pocket pro-
tein” family possessing functional redundancy. Critical increase in the efficacy of theMSCs based
cell therapy will depend on precise understanding of various aspects of the pRb-E2F signaling.
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MSCs are a type of somatic stem cells (SSCs) for non-
hematopoietic tissues of mesodermal origin possessing self-
renewal and capable to differentiate into bone, fat, and
other lineages of connective tissue.1e4 Under special
metabolic conditions MSCs may transform into cells of un-
usual ecto- or endoderm phenotypes including neurons or
epithelium.5 During last 5 years, the number of registered
MSCs clinical trials have increased by about 10 folds. This
reflects general viewpoint that MSCs present a new prom-
ising resource for cell therapy. MSCs produce a variety of
humoral factors promoting efficacy of the regenerative
therapy.6 Effective tissue reconstitution is based on the
replacement of damaged cells by MSCs that are capable to
the tissue specific differentiation. Epigenetic reprogram-
ming of MSCs underlies their differentiation and plasticity,
both of which include fate determination and terminal
differentiation. Currently, the mechanisms of terminal
differentiation have been well documented for bone, fat,
and muscle cell lineages,1,4 whereas the cell fate deter-
mination is still remained to be investigated.
The key role of signaling pathways in altering cell fate
has recently been demonstrated for Wnt/b-catenin
signaling. The Wnt3a ligand immobilized to beads and
attached to single dividing embryonic stem cell (ESC)
induced asymmetric distribution of centrosome, mitotic
spindle and downstream components of the Wnt/b-catenin
signal pathway (Lrp6, Apc, b-catenin) to the daughter cell
proximal to the ligand location. The ligand attached cell
retained self-renewal potential while its distal sister
became committed. Under the same condition, the Wnt5a
ligand transmitting noncanonical Wnt signals did not change
the symmetry of division.7 These results show that Wnt/b-
catenin pathway plays key role in the fate cell choice of
ESCs, however, do not provide evidence for the signals
initiating asymmetric division under normal conditions.
In making decision to divide or not, the cell accumulates
external and internal signals helping to overcome the
negative barrier imposed by the protein of pRb family,
collectively named as “pocket proteins”.8 Pocket proteins
are deprived of DNA binding site and regulate cell cycle
progression through binding and suppression of E2f tran-
scription factors.9,10 Mitogen signals promote phosphoryla-
tion of pocket proteins and liberation of E2fs which induce
synthesis of proteins required for cell cycle progression.11
Orthologs of the pRb-E2F pathway present in some unicel-
lular and all multicellular organisms and seems to play key
role in multicellular development due to their central po-
sition in regulation of cell cycle, cell fate and differentia-
tion.12 Currently, basic pRb-E2F function is considered to be
associated with cell cycle regulation and tumor suppres-
sion.8,13 However, the structures of the ancestral pRb-E2fs
molecules are more similar to p107/p130-E2f4,5 that play
role of quiescence gate keepers in complex self-renewing
organisms.14 RB1 and E2F1-3 functions in development
were related to diversification of cell cycle, regulation of
apoptosis, metabolism and tumor suppression.12 Lin35, the
only ortholog of pocket proteins in C. elegans, is more
related to p130/p107 than to pRb and does not contribute
to G1/S transition.15 Lin35 interacts with Efl-1, an orthologof E2fs, to form the core of DRM complex regulating vulva
cells differentiation in C. elegans.16 The ortholog of E2fs in
Drosophila, dE2f1, similar to E2f1-3 in mammals, activates
cell proliferation, while dE2f2 forms repressive complexes
with pRb orthologs, Rbf1 or Rbf2.17 In plants, pRb ortholog,
RBR, determines cell fate of meristem stem cells
committed into different tissue specific cells in embryonic
and postnatal life.18 In contrast to animals, organs in plants
develop post-embryonically, the meristem cells change
their fate after germination when seedling switches from
heterotrophic to autotrophic growth and later, when the
vegetative apical meristem began to produce flowers.19
Various turns in cell fate regulated by RBR in plants,
possibly, correspond to similar mechanisms in animals. In
mammals, the homolog of DRM, DREAM, suppresses
expression of more than 800 E2fs responsive genes at G0
phase of cell cycle that associates with combined regula-
tion of cell cycle and differentiation.20 Roughly, in plants
and animals pRb-E2F pathway regulates cell cycle, cell
fate, and cell differentiation.
Mesenchymal stem cells as a type of tissue
specific adult stem cells
The honor for discovery of MSCs belongs to Russian scientist
A. Friedenstein and his coworkers. In search for osteogenic
precursors, they found that bone marrow cells in culture
form colonies of fibroblast like cells possessing a key
feature of stem cells e clonogenicity.21 When introduced in
cell impermeable chamber into abdominal cavity of syn-
geneic recipients, these cells retain clonogenic ability and
form bone in the course of repeated transplantation.22
These experiments demonstrated that bone marrow
derived MSCs have self-renewal and differentiation capac-
ities and thus may be addressed as a type of SSCs. Later,
results of Dr. A. Friedenstein were confirmed and devel-
oped. It was found that MSCs from human bone marrow
possess multipotency and are inducible to differentiation
into fat, bone and chondrocyte lineages under definite
conditions.4 MSCs were found in all studied tissues
(including peripheral blood) of adult animals belonging to
various species.23e25 Due to ability to accept unusual
phenotype termed plasticity,5 immunomodulating abil-
ity26,27 and secretion of humoral factors activating endog-
enous mechanisms of regeneration, MSCs became a
valuable new source for cell therapy.28,29 MSCs show effi-
cacy in cell therapy of variety of degenerative, inflamma-
tory, traumatic, and immune diseases of various organs.30
This suggests that MSCs contribute to different mecha-
nisms of regenerative therapy, the biological basis of which
needs to be studied in future.
There are still no specific markers for MSCs. Interna-
tional Society for Cellular Therapy defined MSCs as being
positive for CD73, CD90, CD105, negative for CD45, CD34,
CD14 or CD11b and differentiate into at least three meso-
dermal cell lines: adipocytes, osteocytes and chon-
drocytes.31 There are also a number of other positive
markers for MSCs the expression levels of which depend on
various conditions that corresponds to their intrinsic het-
erogeneity29 and variability in culture.32 MSCs reside in
connective tissue of all postnatal organs,24,25 however,
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is widely accepted that postnatal MSCs have mesodermal
origin.33 MSCs from distinct tissues reveal different func-
tional and marker abilities.34e37 It is unclear if these dif-
ferences are linked to the MSCs origin or result from action
of specific tissue environment. To find out whether tissue
specific MSCs originate from one or several cell types, Sagi
and colleagues38 performed comparative study of expres-
sion of 177 genes in MSCs cell lines established from adult
adipose tissue (AAD), adult bone marrow (ABM), juvenile
spleen (JSpl), juvenile aorta (JAo), and juvenile thymus
(JThy). The authors found that MSCs from any source do not
express markers of pluripotency (Oct4, Rex-1, Nanog), do
express typical stromal markers and are characterized by
distinct patterns of the HOX gene expression corresponding
to their anatomical location: JThy express TBX5 and PITX2,
JSpl e TLX1 and NKX2.5, femoral ABM e PITX1, and JAo e
EN2. These MSCs features are stable in long-term culture.
The authors concluded that tissue specific MSCs descent
from mesodermal precursors developing in the course of
body segmentation.38
The difference in molecular imprinting of MSCs from
various tissues may directly associates with their distinct
regenerative potential that was demonstrated by repair of
damaged myocardium,39 differentiation into myocytes of
distrophyc mice,40 and modulation of immune response.41
Functional interplay between tissue specific stem cells and
surrounding mesenchyme was found in various organs.
Thymic stroma produces factors that induce generation of
mature T-cells.42 Regulation of proliferative activity in the
bladder urothelium of adult animals occurs via Shh andWnt/
b-catenin signals exchange between mesenchyme and pa-
renchyma.43 MSCs from murine fetal hearts express the
precursor cell markers, Isl1 and c-kit, that indicates rela-
tionship between mesenchyme and parenchyma in the same
organs.44 MSCs from murine adult bladder do not possess
clonogenic and differentiation capacities in contrast to em-
bryonic bladder MSCs and adult bone marrow MSCs.45 In
correspondence with these data, cardiac fibroblasts can be
reprogrammed into cardiomyocytes more effectively than
the tail skin fibroblasts.44 Molecular imprinting and corre-
sponding differences inmarker profiles, ability to proliferate
and differentiate into distinct lines in MSCs from various
tissues may be termed for short as “tissue imprinting”.
MSCs in culture represent a heterogenous population
consisting of multi-, bi- or unipotent lineage restricted
progenitors and fibroblasts lacking differentiation poten-
tial.28,46 The serial analysis of gene expression showed that
MSCs transcriptome contains a variety of transcripts that
play a role in the specification of mesoderm, lineage spe-
cific mesodermal derivatives and regulation of the MSCs
induced engraftment.28,47 Currently it is widely accepted,
that efficacy of MSCs mediated cell therapy is mostly based
on their humoral effects. Inversion of MSCs into tissue
specific cells of damaged tissues may greatly enhance the
clinical significance of this recourse in treatment of widely
distributed diseases. The condition which critically limits
the MSCs therapeutic efficacy is misunderstanding of the
mechanisms regulating cell fate choice. The origin of line-
age restricted progenitors and determination of cell fate
occur in G1 phase of cell cycle via interaction of several
signal pathways including the pRb-E2F.General view of pRb-E2F signaling
pRb was the first tumor suppressor to be cloned.48,49 The
pRb loss causes retinoblastoma e rare form of eye chil-
dren’s cancer that occurs in high or low penetrant forms
depends on type of the RB mutation.50,51 pRb is an ubiq-
uitous negative regulator of cell cycle progression in all
tissues of multicellular organism and the founder member
of the pocket protein family which includes two other
proteins: p107 and p130 (Fig. 1).52,53 Structurally, p130 and
p107 are more related to one another than to pRb, are
expressed, accordingly, in quiescent and proliferating cells,
while pRb activity is determined at all cell cycle stages.54,55
In contrast to pRb, p107 and p130 are able to bind and
inhibit cyclin E/A-Cdk2 in regulation of S phase entry and M
phase exit.56e58 Pocket proteins do not possess DNA binding
domain and regulate cell cycle progression via interaction
with E2f transcription factors.9,59 E2f family includes 9
proteins. E2f1-5 possessing the ability to bind pocket pro-
teins are divided into activators (E2f1-3) and suppressors
(E2f4,5). F2f4-5 accumulate in quiescent, while F2f1-3 e in
proliferating cells. Activator and suppressor E2fs bind
distinct pocket proteins: F2f1-3 e pRb, while F2f4,5 e
r107/r130, that allow pocket proteins to regulate different
E2f-responsive genes.54,60 E2fs bound to a pocket protein
lose the ability to activate transcription because pRb
binding site is located inside E2fs transactivation domain.59
E2fs activate transcription when form dimers with Dp pro-
teins.8,10,52 When unbound to pocket proteins E2fs activate
transcription of many genes the products of which are
required for G1/S transition, replication and mitosis. Inhi-
bition of E2fs transcriptional activity induces cell cycle
arrest.8,10
Whichever signal impinges on cell of multicellular or-
ganism it is processed at cell cycle check points to make
decision what to do: commit to another round of division,
exit the cell cycle or change the cell fate. The key regulator
of the cell cycle control system making this decision is pRb-
E2F pathway which is highly conserved in development. The
orthologs of pocket and E2fs proteins are present in uni-
cellular plants and animals.12 RB and E2F ancestral genes
divided, correspondingly, into RB1 (including RB1), RBL
(including RBL1/p107 and RBL2/p130) subgroups, while E2F
e into E2F4/5 (including E2F4 and E2F5) and E2F1/2/3
(including E2F1, E2F2, E2F3) subgroups before placozoans
and bilaterians diverged. Members of RBL and E2F4/5 sub-
groups show more sequence similarity, correspondingly,
with RB and E2F ancestral sequences, than members of RB1
and E2F1/2/3 subgroups. These results suggest that
ancestral of p130/p107 and E2f4/E2f5 proteins might
represent more ancient function of pRb-E2F signaling
associated with control of quiescence and cell fate
choice.12 In C. elegans, Drosophila, and mammals the
DREAM complex was identified which includes as core
element the p130/E2f4/Dp proteins and functionally
directed to keep quiescence.16,20,61 The outlined data
suggest that pRb-E2F signaling creates mechanism for cell
fate choice to shift from proliferation to transient or
constitutive quiescence including long last G0 state, dif-
ferentiation or cell senescence. On the other hand, the pRb
in complex with activator E2fs might contribute to
Figure 1 Comparative structures of pocket proteins.A. Domain structure of pRb and list of pRb-binding proteins. B. Comparative
structures of human pRb, p107, j p130. The pocket proteins structures reveal high levels of homology in A and B domains composed
of the cyclin folds. The similar tandem cyclin folds were found in the N-terminus of all pocket proteins. The B-domain of small
pocket contains binding site for the LxCxE motif detected in many functionally different molecules including oncoproteins. The
small pocket and proximal part of the C-terminus form the large pocket mediating interactions of pRb with E2fs and cyclins. The
p107 and p130 do not show homology with pRb outside the A, B and N-domains and are more similar to each other than to pRb.
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tumor suppression via control on all aspects of cell cycle
and coupling cell cycle with differentiation, cell senes-
cence and apoptosis.12,17
Among all pocket proteins only pRb owns function of
tumor suppressor and is functionally inactivated in all types
of human cancer.62,63 However, pocket proteins show fea-
tures of functional redundancy the physiological relevance
of which is currently not completely clear.64 DNA micro-
array analysis showed that pRb deficiency targets genes
encoding cell cycle regulatory proteins.65 These genes were
previously shown to be regulated by E2F1-3.66,67 In
contrast, loss of p107/p130 alters expression of genes
regulating quiescent state in response to growth or differ-
entiation signals.65 Some genes showed overlapping pattern
of regulation by pRb and p107/p130. This may reflect the
consistency of regulation of the same genes by pRb blocking
their activity through interaction with E2f1-3 followed by
stable repression of these genes with p130/E2f4.65,68 Evi-
dence of functional redundancy among pocket proteins in
interaction with separate genes and regulation of separate
functions were supported by the demonstrations of
immortalization, loss of differentiation ability and sensi-
tivity to cell senescence signals in fibroblast lacking all
pocket proteins. In contrast, none of other knockout com-
binations induced these functional defects.69,70
Cell cycle regulation
pRb/E2f4 and p130/E2f4,5 complexes induce transient cell
cycle arrest in G1 by suppression of transcription of genes
required for replication and mitosis.71,72 Similar growth ar-
rest is induced in response to serumdeprivation, DNAdamage
or action of TGFb growth factors,73e75 while permanent cellcycle exit occurs during cell differentiation and senes-
cence.76,77 Mitogens activate cyclins D/Cdk4-6 complexes
leading to eventual phosphorylation and inactivation of pRb
from early G1 phase to mitosis (Fig. 2).78e80 pRb phosphory-
lations by Cdks on multiple phosphorylation sites induce
unique conformations of pRb altering its ability for different
protein interactions81 and releasing of E2fs which promote
cell cycle progression.82,83 Similar mechanism underlies the
transforming effect of the oncogenic viruses the products of
which bindpocket proteins and convert E2fs into constitutive
activators of transcription.10,84 In G1/S transition pRb
changes its partner from E2f4 to E2f1, while p130 is down-
regulated and degraded.85 The rest of p130 in complex with
E2f4 is converted into p130/E2f4/cyclinE/A-Cdk271,72 and
loses its suppressor activity. DREAM complex after G1/S dis-
sociates from p130 and changes it to Myb.20 G1/S transition
and followed DNA replication are initiated by expression of
cyclin E which downregulates pocket proteins and upregu-
lates E2f1-3.8 The activator E2fs induce expression of cyclin
A, Pcna, Mcm2-7, Cdc6 and other proteins of replication
machinery whose production are negatively regulated by
pocket proteins.86 pRbnegatively regulates expression of the
mitotic checkpoint protein Mad2 which in its turn down-
regulates the anaphase promoting complex (Apc). Loss of
pRb causes overexpression of Mad2, premature chromosome
segregation, aneuploidy and tumor formation.87,88 In
Drosophila, a pRb ortholog, RBF, interacts with the CAP-D3
condensin complex subunit promoting chromosome
condensation during prophase.89 Under pRb deficiency,
mammalian cells show decreased interaction of condensin II
with chromatin, hypocondensation of chromosomes and
delayed progression to metaphase.90
The rate of cancer progression in patients with retino-
blastomas is mostly related to epigenetic, but not to
Figure 2 Pocket proteins connect outside signals with the cell cycle control system regulating cell proliferation. A. Direct
sequence of the cell cycle phases. B. Basic components of the cell cycle control system. Mitogens induce synthesis of cyclin D which
forms active kinase complexes with Cdk4-6. Cyclin D is under negative control of p15Ink4b/p16Ink4a inhibitors. Cyclin D/Cdk4-6
phosphorylate pRb and liberate E2fs which promote synthesis of cyclins E/A/B required for initiation and progression of DNA
replication and mitosis. Cyclins eventually phosphorylate pRb until end of mitosis. p21Cip1, p27Kip1 and p57Kip2 are CdkI inhibiting
Cyclin E/A; SCF and APC are ubiquitin ligases promoting periodical inactivation and degradation of the cell cycle regulatory
proteins.
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lations on multiple sites during cell cycle progression which
induce diverse conformational changes in its structure.92
There are few known RB mutations that cause retinoblas-
toma, however, they do not induce discrete loss of its
functions.93 Some low penetrance forms of retinoblastoma
have been analyzed to study pRb role in cell cycle
signaling.94,95 The product of a native pRb mutation R661W
that causes formation of the low penetrance retinoblas-
toma, does not bind activator E2fs but retains the ability to
interact with repressor E2fs. In vitro the low penetrance
mutants show some activity in proliferation control and
induce differentiation in the pRb deficient Saos-2 cell
line.51 In experiments in vivo with the knock in R661W were
obtained similar results.96 Using a panel of synthetic pRb
pocket mutants it was shown that cell cycle and differen-
tiation capacity of pRb are genetically and mechanistically
separated.97 There are two mechanisms by which the low
penetrance pRb mutants may retain partial functional ca-
pacity. First, they retain the ability to bind suppressor E2fs.
A pRb mutant with small deletion at the end of T antigen-
binding site showed higher affinity for E2f4 compared to
E2f1, formed complex with E2f4, retained tumor suppressor
activity and induced early muscle commitment more
effectively than the wild type pRb.98 Low pRb penetrance
mutants may also control cell cycle progression through
their capacity to inhibit Skp2 mediating ubiquitination and
degradation of p27 CdkI.99 C-domain of pRb binds Skp2
while small pocket simultaneously interacts with Cdh1
component of Apc making conditions for ubiquitination and
degradation of Skp2.100 This allows p27 CdkI to escapedegradation and to block the activity of Cdks through pRb
phosphorylation.Regulation of cell fate via chromatin
modifications
pRb can alter cell fate via different types of chromatin
modifications: 1) via recruiting of co-repressors when bound
to a gene promoter by E2fs, 2) through interaction with
proteins of Polycomb (PcG) family; 3) by regulation of
genome wide formation of heterochromatin domains, per-
icentric heterochromatin, telomeres, and senescence-
associated heterochromatin foci (SAHF).101 When bound
to E2fs, pRb can induce active suppression of transcription
at local chromatin areas by recruiting functionally distinct
molecules to the gene promoters encompassing E2fs bind-
ing sites. The list of the bound proteins contains function-
ally different molecules: DNA methyltransferases
(Dnmt1),102 histone deacetylases, (Hdac1,2),103 histone
methyltransferases (Suv39h1/2, Suv4-20h1/2),104 histone
demethylases (Rbp2),105 chromatin-associated proteins of
Hp-1 family,106 key components of chromatin remodeling
complexes.107 pRb regulates stability of Dnmt1 methylating
promoters of some regulatory genes. Inactivation of pRb
results in abnormal DNA methylation and malignant pro-
gression.108 One of the well studied chromatin modification
is histone deacetylation followed with histone methyl-
ation.109,110 Interaction of pRb proteins with Brg1 and Brm
e the ATPase components of the SWI/SNF nucleosome
remodeling complexes, may regulate translocation of
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variants to repress or activate transcription.111,112 The
mechanism of interaction of Brg1 and Brm with pocket
proteins is still undefined.113 At the same time, its func-
tional significance is evident, since genetic inactivation of
these proteins in mouse model in vivo results in hyper-
proliferation and tumor formation.114
Generation of facultative heterochromatin by Polycomb
(PcG) proteins is initiated via trimethylation of H3K27 on
promoters of regulatory genes followed by the establish-
ment of stable repressive complexes on this histone
mark.115 This chromatin modification is induced by Ezh2
methyltransferase e a component of the PcG repressive
complex 2 (PRC2),116,117 the expression of which is under
control of pRb.118 Inactivation of pocket proteins abolishes
H3K27 trimethylation on promoters of many genes including
the p16 CdkI,119 which functionally associated with regu-
lation of cell cycle, cell senescence and cancer.120 The
mechanism for PRC2 recruitment to target genes in verte-
brates is still unknown. At the same time, it was established
that it may be mediated by the RbAp46/48, a component of
PRC2, which indirectly binds pRb.121
Although role of pRb family in formation of the PcG
mediating gene silencing is commonly recognized, its
functional significance much more exemplified in plants
than in animals. In Arabidopsis the germ line evolves from
uncommitted cells in floral meristems.122 Loss of RBR allele
alters cell determination, induces activation of nuclear
division and misexpression of specific markers in female
and male gender cells.123 Specification of gametes in Ara-
bidopsis depends on appropriate interplay between RBR
and PRC2. RBR is required for cell differentiation of male
and female gametophytes. Loss of RBR perturbs expression
levels of the DNA methyltransferase 1 (MET1), a subunit of
PRC2. Additionally, RBR binds MET1 which regulates main-
tenance of heterochromatin. PRC2-specific H3K27-
trimethylation activity represses paternal RBR, suggesting
reciprocal RBR-PRC2 regulatory circuit that is important for
the reproductive cells development.124 The RBR-PRC2
interaction may present an established net to control
gametogenesis and expression of imprinted genes evolved
prior to the separation of animal and plants.125,126 Loss of
RBR results in hyperproliferation in Arabidopsis late
embryogenesis, while after germination the seedlings are
unable to shift from heterotrophic to autotrophic growth
that associates with inappropriate expression of late em-
bryonic genes controlled by PRC2 through H3K27 trime-
thylation.127,128 Plants in contrast to animals maintain pools
of totipotent cells in meristems during all life to form new
organs and promote sporophytic development.129 Condi-
tional loss of RBR in Arabidopsis prevents differentiation of
stem cells and increase in their pool,18 while transient
expression of RBR in the tobacco shoot apical meristem
induces opposite result by activating stem cells
differentiation.130
pRb can alter cell fate by supporting cell senescence
through formation of SAHF,131,132 pericentric chromatin and
telomeres.104 pRb is able to bind Suv39h1/2 methyl-
transferases, which trimethylate H3K9 and constitute
binding site for chromo domains of HP-1 proteins.133 Em-
bryonic knockout of RB causes sharp decrease in H3K9
methylation and HP-1 enrichment in cyclin E promoter.106When bound to histones the Suv39h1/2 create new bind-
ing sites for HP-1 proteins on newly synthesized DNA pro-
moting the spread of heterochromatin and formation of
SAHF. H4K20me3 is another genome-wide modification of
chromatin which is composed under control of pocket
proteins. In triple knockout mice H4K20me3 levels decrease
in all heterochromatin domains: telomeres, long inter-
spersed nuclear elements and pericentric heterochromat-
in.134,135 pRb as well as p130 and p107 physically bind Suv4-
20h1/h2 methytransferases which trimethylate H4K20.104pRb proteins in fate determination and
differentiation of MSCs
Mechanism of asymmetric division includes unequal distri-
bution of cell polarity factors and cell fate determinants
between daughter cells. Well studied players of this
mechanism in C. elegance and Drosophila are Par complex
and Numb protein.136,137 However, triggers of asymmetric
cell division and their connection to pocket proteins are
still waiting to be discovered. pRb-E2f signaling acts as the
switch altering functional status of the cell and thereby
changing its fate.138 Additionally to the switch from pro-
liferation to quiescence associated with differentiation,
pRb regulates E2f1 mediated apoptosis67 and cell senes-
cence.131,132 In C. elegans, pRb ortholog Lin35 determines
cell fate during larval development. Combined inactivation
of LIN35 and a synthetic multivulva B (synMuv B) genes
causes hyperproduction of vulva cells during larval devel-
opment. Under normal conditions the products of LIN35,
EFL1 (an E2F ortholog in C. elegans) and synMuv B genes
form DRM complex providing transcriptional repression of
the LIN-3/EGF (epidermal growth factor) gene regulating
proliferation of vulva precursor cells.139,140 Additionally,
Lin35 maintains repressive status of chromatin at germline
specific genes in somatic cells and its mutation causes
transformation of somatic into germline cells.141,142
pRb may induce differentiation by sequestering its in-
hibitors Eid-1 and Id2. Eid-1 mediates degradation of the
p300 histone acetylase, a co-activator of MyoD transcrip-
tion.143,144 Id2 inhibits myogenic differentiation by binding
and sequestering the E2 factors which form heterodimers
with proteins of MyoD family to activate the tissue specific
transcription.145,146 pRb also binds and inactivates Rbp2/
Kdma5 H3K4 demethylase.105 H3K4me3 mark associates
with active status of chromatin and its demethylation shifts
the balance to differentiation. It was found more recently
that in terminally differentiated cells common Kdm5a and
E2f4 targets are bound not by pRb but p130 and DREAM
complex.147
pRb loss in progenitors of various tissues causes their
expansion, blockage of differentiation and initiation of tu-
mors.70 Genome wide analysis in mammalian fibroblasts and
C. elegance showed that Utx/Kdm6A (Utx after) activity
promotes pRb signaling. Inactivation of Utx changes the cell
fate and initiates malignant transformation.148 The ques-
tion raises what function of pRb is primarily associated with
tumor formation? Because retinoblastoma cells express
markers of multiple cell lines, one may suggest that retina
cells lacking RB lose the ability to control fate determina-
tion and establish or maintain the tissue specific
180 B. Popov, N. Petrovdifferentiation profile.138 There is a new viewpoint that Rb
family members promote general organization of chro-
matin.149 Presumably, all effects of pocket proteins previ-
ously addressed in the context of regulation of separate
genes, should be reevaluated as results of activity of pro-
tein complexes at specific locations in the genome.
pRb influence on differentiation includes its direct in-
teractions with variety of tissue specific transcription fac-
tors beyond pRb-E2F pathway. List of these factors
regulating specification of MSCs into osteoblasts includes
Runx2,150 adipocytes e C/Ebps and Pparg,151,152 myocytes
e MyoD.153,154 In these cases pRb acts as transcriptional
activator of terminal differentiation by promoting induc-
tion of tissue specific master genes. The pRb specific role in
early stages of differentiation is still unclear.Bone differentiation
Bone and fat unipotent precursors evolve from bi-potent
ancestral MSCs on alternative basis (Fig. 3) by an epigenetic
switch regulated by histone H3K27 methyltransferase,
Ezh2, and demethylase, Utx.155 Ezh2 and Utx exhibit an
inverse expression pattern during MSCs osteogenic and
adipogenic differentiation. Ezh2 acts as the negative
regulator of osteogenesis and positive regulator of adipo-
genesis of human MSCs, whereas Utx induces opposite ef-
fects.156 The master osteogenic regulator, Runx2,150 is
repressed during adipogenic differentiation due to strong
increase in H3K27me3 on the Runx2 transcription start site.
Ezh2 represses transcription and increases histone
H3K27me3 level for the downstream Runx2 targetsFigure 3 Role of the pRb signaling in differentiation of MSCs in
includes the cell fate determination and terminal differentiation p
tiation potential is eventually limited and the cells form three-, b
interacting with distinct signal pathways including Wnt/b-cateni
directed by the tissue specific transcription factors the nature of wosteopontin, and osteocalcin.155 Conversely, Runx2,
osteopontin and osteocalcin transcripts are upregulated by
Utx that coincides with downregulation of H3K27me3.
Presumably, Ezh2 trimethylates H3K27 on the promoters of
Runx2 and its downstream targets causing inhibition of
these genes expression. Utx acts in opposite direction by
removing H3K27me3 and promoting osteogenic differenti-
ation.155 Active status of Utx in MSCs is supported by pRb
pathway. The genome wide Gene Ontology analysis found
that in fibroblasts Utx occupies 49 genes associated with
the pRb pathway.148 Loss of Utx ortholog (dKdm6a) in
Drosophila results in increased proliferation due to sup-
pression of Notch and pRb pathway.157 On the protein
levels, pRb binds Runx2 through small pocket and form
complex which is detected at the promoters of its tar-
gets.150 pRb maintains differentiation status of bone tissue.
The bone specific pRb inactivation in mice causes dedif-
ferentiation of the osteoclasts.158 Additionally, pRb pro-
motes Runx2 mediated activation of p27 CdkI that turns on
feedback signals and keeps pRb in active hypophosphory-
lated form.150 Patients with retinoblastoma are predis-
posed to growth of osteosarcoma in teenager’s age that
gives evidence of specific role of pRb in proliferation of
osteoblast cell line compare to all other MSCs derived
lines.64Fat differentiation
Ezh2 shows negative regulation of osteogenesis while Utx e
negative regulation of adipogenesis for murine and human
MSCs.156 Inhibition of the methyltransferase activity usingto adipocytes, osteocytes, and myocytes. MSCs differentiation
hases. In the course of cell fate determination MSCs differen-
i-, and unipotent precursors. This process is regulated by pRb
n, BMP, TGFb, Notch and others. Terminal differentiation is
hich has been determined.
pRb-E2F signaling and mesenchymal stem cells 181siRNA mediated knockdown or chemical reagents demon-
strated existence of epigenetic Utx switch enhancing fat
differentiation when level of Ezh2 elevated while level of
Utx dropped. In freshly harvested human MSCs the pro-
moters for adipogenic genes PPARg2, leptin, fatty acid-
binding protein 4, lipoprotein lipase are hyper-
methylated,159 but became hypomethylated after induc-
tion of fat differentiation by overexpression of Ezh2.160 In
contrast, under conditions of Ezh2 hyperexpression, pro-
moters of RUNX2, osteocalcin, and osteopontin became
hypermethylated and expression of these genes was sup-
pressed.155 The possible mechanism of activation of the
Ezh2 mediated fat differentiation may include the alter-
native repression of WNT genes that are negative targets of
Ezh2.161 It is possible that Ezh2 represses osteogenesis at
multiple levels by direct affecting WNT genes that upre-
gulate Runx2 and its downstream targets.162 Simulta-
neously, Ezh2 activates adipogenesis which is active by
default in the case of suppression of osteogenesis. In the
course of determination of fat differentiation MSCs are
triggered by appropriate stimuli to make cell fate choice,
then they become restricted to the adipocyte lineage and
generate preadipocytes. After that, induced preadipocytes
undergo multiple rounds of proliferation (mitotic clonal
expansion) followed by terminal differentiation.163
Wnt/b-catenin signaling activates commitment and in-
hibits terminal fat differentiation.164 Forced expression of
Wnt10b maintains undifferentiated status of preadipocytes
that is mediated by inhibition of activity of the master fat
differentiation factors, C/Ebpa and Pparg. Wnt10a,b and
Wnt6 through b-catenin attenuate adipogenesis and acti-
vate osteogenesis of committed cells. Inactivation of b-
catenin prevents inhibition of adipogenesis and activation
of osteogenesis by these factors. Transgenic mice consti-
tutively expressing high levels of Wnt10b produce less fat
tissue than normal animals.165 Mutation of C256Y in struc-
ture of WNT10b abolishes its ability to activate b-catenin
and leads to obesity.166 Inhibition of b-catenin signaling by
expression of dominant-negative form of Tcf4 enhances fat
differentiation and promotes reversion of myoblasts into
adipocytes. The expression of some proteins transmitting
Wnt signals, such as R-spondins2,3, Wnt1, transcription
factors Tcf1,3,4 is significantly elevated in the A33 pre-
adipocytes, compared to maternal cells. b-catenin accu-
mulates in A33 cells nuclei and causes elevation of the
levels of Lef/Tcf.167 Possibly, Wnt signals promote produc-
tion of Bmp4, which in its turn induces appearance of
preadipocytes by inducing transcription factors C/Ebpb and
Pparg. These tissue specific master factors induce terminal
stage of fat differentiation (Fig. 3).168 On the other hand,
Wnt/b-catenin signals inhibit terminal stage of fat differ-
entiation. Wnt10b attenuates formation of fat cells by
decreasing activity of Pparg, whereas reduction of Wnt10b
production, in opposite, results in activation of adipo-
genesis.169 Obviously, Wnt/b-catenin signals support gen-
eration of proliferating preadipocytes. However, positive
role of these signals turns into negative when preadipocytes
become quiescent during initial step of terminal
differentiation.163
There are two types of fat tissues: white (WAT) and
brown (BAT). Brown fat is found only in mammals and its
color depends of big number of mitochondria. Function ofBAT cells is linked to Ucp1 (uncoupling protein-1) promoting
energy expenditure at the expense of its intake in WAT.170
pRb signaling promotes the MSCs fate choice to WAT
commitment. Embryonic fibroblasts derived from mice
(MEFs) with RB embryonic knockout, are not sensitive to
induction of fat differentiation in vitro.151 This defect may
be eliminated by forced Pparg expression.171 These results
support the idea that pRb promotes differentiation of MSCs
into preadipocytes that eventually generate WAT. Oppo-
site, pRb loss facilitates generation of BAT (Fig. 3).152
Elimination of pRb results in elevation of the Usr1 levels.
MEFs derived from RB-/- mice express Usr1 on the level
similar to that in BAT adipocytes. This suggests that under
normal conditions pRb plays role of the differentiation
switch promoting formation of WAT at the expense of
CAT.172 The WAT adipocytes with low expression of pRb
show increase in number of mitochondria, elevate the
CAT-specific expression and decrease in the WAT-specific
one.173 Loss of pRb in MEFs results in elevation of the
levels of myogenin and heavy chain of muscle myosin.
Possibly, pRb inhibits commitment of MSCs into common
precursors of myocytes/CAT.174 On the other hand, CAT
phenotype recapitulates after pRb loss in mature WAT cells
according to energy expenditure, oxygen intake, elevation
of thermogenesis and increase in the number of
mitochondria.175Muscle differentiation
Myocytes are generated from ancestral mesodermal cells in
the course of early and terminal commitment. Myoblasts
which are formed during early commitment express tissue
specific master factor MyoD and an early muscle marker
desmin, but still proliferate.176,177 Under serum depriva-
tion, MyoD turns on full program of striated muscle differ-
entiation (Fig. 3) which includes eventual expression of
Myf-5, myogenin, and MRF4. These factors induce forma-
tion of nondividing myotubes and production of terminal
muscle markers like myosin heavy chain.178e181 The func-
tional status of pocket proteins in regulation of MSCs dif-
ferentiation is epigenetically regulated by Ezh2/Utx
switch.148 Ezh2 trimethylates O3L27 at RB and RB-associ-
ated genes promoters supporting their suppression by the
Polycomb repressive complex 1 (PRC1), while Utx deme-
thylates O3L27me3, enhances active status of RB gene set
and prevents the cells proliferation.148 Being active, the
pocket proteins activate differentiation regulating the
Ezh2/Utx switch on promoters of master tissue specific
factors. Determination the cell fate occurs in dividing cells
in which pRb interplays with proteins transmitting the Wnt/
b-catenin signals. pRb loss in these cells promotes prolif-
eration of satellite cells and increases in population of
postnatal myoblasts.182 The satellite cells in postnatal life
present stem cells for striated muscle but retain the ca-
pacity to differentiate into adipocytes.183 Possibly, the pRb
ability to regulate cell fate choice between muscle and fat
cell is mediated via its interaction with Wnt/b-catenin
pathway. Hyperproduction of R-spondins activates the
Wnt/b-catenin signal pathway, while injection of recom-
binant R-spondins enhances expression of mRNA of the
tissue specific muscle factor Myf5 in myoblasts S2S12 and
182 B. Popov, N. Petrovprimary satellite cells.184 R-spondins promote myogenic
differentiation and induce formation of hypertrophic myo-
tubes in C2C12 cell line. Inversely, somatic knockdown of R-
spondin genes downregulates Myf5 expression and myo-
tubes formation. In MSCs b-catenin binds the p130/E2f4
complex and alters its ability to inhibit proliferation.185
The described results provide evidence that pRb and
Wnt/b-catenin pathways may mutually interact each other
to regulate fat and muscle differentiation. Fine details of
this interaction and its inductive influence on fat determi-
nation are to be studied in future. Our results suggest that
constitutive expression of functional pRb in polypotent
10T1/2 cell line enhances fat differentiation in contrast to
pRb functional mutant which acts in opposite direction
suppressing fat but activating muscle differentiation.98,186
These results correspond to recent published data that
activation of one type of mesodermal differentiation, for
example, differentiation into WAT inhibits the alternative
MSCs commitment into bone or BAT.152,172 In the experi-
ments in vivo performed 6 months after tissue specific
inactivation of RB, the number of satellite cells in murine
muscle tissue increased by 5 folds and the number of
myoblasts e by 3 folds.182 These results suggest that pRb
inhibits determination of ancestral cells to muscle lineage.
Presumably, myoblasts and BAT cells are derived from
common ancestral precursor for muscle and BAT cells, the
formation of which is suppressed by pRb (Fig. 3).Conclusions
During last decade, the cell therapy based on trans-
plantation of MSCs became promising in treatment of
various widely distributed and dramatic diseases. Further
expansion of these clinical trials is limited due to low
engraftment efficacy of MSCs and non-availability of
methods for directed regulation of their differentiation and
plasticity. Cell differentiation of MSCs is initiated at G1
phase of cell cycle via interaction of mediators of different
signal pathways with ubiquitous pocket proteins. Together
with E2f transcription factors, pocket proteins form pRb-
E2F pathway regulating cell cycle progression. Functional
inactivation of pRb leads to deviations in cell cycle and
underlies cancer formation. Recent evidence suggests that
ancient function of the pRb-E2F signaling was to regulate
cell quiescence, cell fate choice and differentiation. The
ancestral molecules transmitting pRb-E2F signals were
closely related to suppressor E2f4,5 and p107/p130, while
pRb and E2F1-3 played roles in diversification of cell cycle
control and tumor suppression. Eventually, p130/E2f4 has
served as core for DREAM complex which controls quies-
cence in mammals and connects it to cell proliferation in
development.20 Pocket proteins reveal features of func-
tional redundancy. Inactivation of all pocket proteins is the
only condition for cells immortalization, loss of differenti-
ation and apoptosis. Presumably, pocket proteins regulate
transcription of overlapping targets via initial blockage of
their activity by pRb/E2F1-3 followed with the deep tran-
scription suppression by p130/E2f4. The stress-induced
senescence in Saos pRb-/- cells may be initiated by exog-
enous pRb which later delegates its role to p130 detected
at the E2f targeted genes promoters.187 pRb may initiatedifferentiation via sequestration of Kdm5a H3K4 demethy-
lase, however, in terminally differentiated cells the Kdm5a
targets are bound by p130 but not pRb.147 Recent publica-
tions support the suggestion, that pRb regulates activity of
enzymes generated key chromatin marks like H3K4me3,
H3K27me3, H4K20me3. Through this ability, pRb functions
as a local chromatin modifier and regulates cell fate choice
by suppressing proliferation of one cell population in favor
of another, inducing differentiation, cell senescence while
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